Please login to the form below

Not currently logged in
Email:
Password:

Zuranolone

This page shows the latest Zuranolone news and features for those working in and with pharma, biotech and healthcare.

Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3

Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3

Although this finding was not statistically significant, there was a ‘numerical advantage’ in favour of zuranolone demonstrated at day 42. ... The most common TEAEs in the zuranolone group included somnolence, dizziness, headache and sedation.

Latest news

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...